Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catheter Precision (VTAK) Other Non-Current Liabilities (2017 - 2025)

Catheter Precision (VTAK) has disclosed Other Non-Current Liabilities for 5 consecutive years, with $12.0 million as the latest value for Q2 2025.

  • On a quarterly basis, Other Non-Current Liabilities rose 40.62% to $12.0 million in Q2 2025 year-over-year; TTM through Jun 2025 was $12.0 million, a 40.62% increase, with the full-year FY2023 number at $7.0 million, changed N/A from a year prior.
  • Other Non-Current Liabilities was $12.0 million for Q2 2025 at Catheter Precision, up from $10.4 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $12.0 million in Q2 2025 to a low of $8848.0 in Q3 2023.
  • A 3-year average of $6.9 million and a median of $7.8 million in 2024 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: surged 110625.59% in 2024, then soared 40.62% in 2025.
  • Catheter Precision's Other Non-Current Liabilities stood at $7.0 million in 2023, then skyrocketed by 40.48% to $9.8 million in 2024, then rose by 22.93% to $12.0 million in 2025.
  • Per Business Quant, the three most recent readings for VTAK's Other Non-Current Liabilities are $12.0 million (Q2 2025), $10.4 million (Q1 2025), and $9.8 million (Q3 2024).